Literature DB >> 23434139

Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents.

Aleem Gangjee1, Nilesh Zaware, Sudhir Raghavan, Bryan C Disch, Jessica E Thorpe, Anja Bastian, Michael A Ihnat.   

Abstract

Inhibition of receptor tyrosine kinase (RTK) signaling pathways is an important area for the development of novel anticancer agents. Numerous multikinase inhibitors (MKIs) have been recently approved for the treatment of cancer. Vascular endothelial growth factor receptor-2 (VEGFR-2) is the principal mediator of tumor angiogenesis. In an effort to develop ATP-competitive VEGFR-2 selective inhibitors the 5-chloro-N(4)-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamine scaffold was designed. The synthesis of the target compounds involved N-(4,5-dichloro-9H-pyrimido[4,5-b]indol-2-yl)-2,2-dimethylpropanamide) as a common intermediate. A nucleophilic displacement of the 4-chloro group of the common intermediate by appropriately substituted anilines afforded the target compounds. Biological evaluation indicated that compound 5 is a potent and selective VEGFR-2 inhibitor comparable to sunitinib and semaxinib.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23434139      PMCID: PMC3602277          DOI: 10.1016/j.bmc.2013.01.040

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  35 in total

1.  Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.

Authors:  Stefan A Laufer; David M Domeyer; Thomas R F Scior; Wolfgang Albrecht; Dominik R J Hauser
Journal:  J Med Chem       Date:  2005-02-10       Impact factor: 7.446

Review 2.  Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

Authors:  Stephen R D Johnston; Alex Leary
Journal:  Drugs Today (Barc)       Date:  2006-07       Impact factor: 2.245

Review 3.  Role of tyrosine kinase inhibitors in cancer therapy.

Authors:  Amit Arora; Eric M Scholar
Journal:  J Pharmacol Exp Ther       Date:  2005-07-07       Impact factor: 4.030

4.  Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

Authors:  P Traxler; G Bold; J Frei; M Lang; N Lydon; H Mett; E Buchdunger; T Meyer; M Mueller; P Furet
Journal:  J Med Chem       Date:  1997-10-24       Impact factor: 7.446

Review 5.  Sunitinib: from rational design to clinical efficacy.

Authors:  Laura Q M Chow; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

6.  2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.

Authors:  Jagabandhu Das; Ping Chen; Derek Norris; Ramesh Padmanabha; James Lin; Robert V Moquin; Zhongqi Shen; Lynda S Cook; Arthur M Doweyko; Sidney Pitt; Suhong Pang; Ding Ren Shen; Qiong Fang; Henry F de Fex; Kim W McIntyre; David J Shuster; Kathleen M Gillooly; Kamelia Behnia; Gary L Schieven; John Wityak; Joel C Barrish
Journal:  J Med Chem       Date:  2006-11-16       Impact factor: 7.446

7.  Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.

Authors:  Cesare Gridelli; Paolo Maione; Filomena Del Gaizo; Giuseppe Colantuoni; Ciro Guerriero; Carmine Ferrara; Dario Nicolella; Daniela Comunale; Alba De Vita; Antonio Rossi
Journal:  Oncologist       Date:  2007-02

8.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Authors:  Risto Kerkelä; Luanda Grazette; Rinat Yacobi; Cezar Iliescu; Richard Patten; Cara Beahm; Brian Walters; Sergei Shevtsov; Stéphanie Pesant; Fred J Clubb; Anthony Rosenzweig; Robert N Salomon; Richard A Van Etten; Joseph Alroy; Jean-Bernard Durand; Thomas Force
Journal:  Nat Med       Date:  2006-07-23       Impact factor: 53.440

Review 9.  Anti-angiogenic drugs: from bench to clinical trials.

Authors:  Ana R Quesada; Ramón Muñoz-Chápuli; Miguel A Medina
Journal:  Med Res Rev       Date:  2006-07       Impact factor: 12.944

Review 10.  The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.

Authors:  Robert L Comis
Journal:  Oncologist       Date:  2005-08
View more
  3 in total

1.  Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.

Authors:  Roheeth Kumar Pavana; Shruti Choudhary; Anja Bastian; Michael A Ihnat; Ruoli Bai; Ernest Hamel; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2016-11-15       Impact factor: 3.641

2.  Design, synthesis and biological activity of pyrazinamide derivatives for anti-Mycobacterium tuberculosis.

Authors:  Shiyang Zhou; Shanbin Yang; Gangliang Huang
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

3.  Design, synthesis, and bioactivity evaluation of antitumor sorafenib analogues.

Authors:  Shiyang Zhou; Guangying Chen
Journal:  RSC Adv       Date:  2018-11-08       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.